JP5856606B2 - Faahの調節薬として有用なオキサゾール誘導体 - Google Patents

Faahの調節薬として有用なオキサゾール誘導体 Download PDF

Info

Publication number
JP5856606B2
JP5856606B2 JP2013506203A JP2013506203A JP5856606B2 JP 5856606 B2 JP5856606 B2 JP 5856606B2 JP 2013506203 A JP2013506203 A JP 2013506203A JP 2013506203 A JP2013506203 A JP 2013506203A JP 5856606 B2 JP5856606 B2 JP 5856606B2
Authority
JP
Japan
Prior art keywords
alkyl
halo
mono
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013506203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525356A (ja
JP2013525356A5 (enExample
Inventor
ナンテルメツト,フイリツプ・ジー
ヤン,ジ−チヤン
クリートソーラス,コンスタンチン
ワルジ,アツバス・エム
チユー,ホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2013525356A publication Critical patent/JP2013525356A/ja
Publication of JP2013525356A5 publication Critical patent/JP2013525356A5/ja
Application granted granted Critical
Publication of JP5856606B2 publication Critical patent/JP5856606B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013506203A 2010-04-22 2011-04-18 Faahの調節薬として有用なオキサゾール誘導体 Expired - Fee Related JP5856606B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32669510P 2010-04-22 2010-04-22
US61/326,695 2010-04-22
PCT/US2011/032842 WO2011133447A1 (en) 2010-04-22 2011-04-18 Oxazole derivatives useful as modulators of faah

Publications (3)

Publication Number Publication Date
JP2013525356A JP2013525356A (ja) 2013-06-20
JP2013525356A5 JP2013525356A5 (enExample) 2014-06-05
JP5856606B2 true JP5856606B2 (ja) 2016-02-10

Family

ID=44834467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013506203A Expired - Fee Related JP5856606B2 (ja) 2010-04-22 2011-04-18 Faahの調節薬として有用なオキサゾール誘導体

Country Status (8)

Country Link
US (1) US9073879B2 (enExample)
EP (1) EP2593102B1 (enExample)
JP (1) JP5856606B2 (enExample)
CN (1) CN103153307A (enExample)
AU (1) AU2011242961B2 (enExample)
BR (1) BR112012023971A2 (enExample)
CA (1) CA2794724A1 (enExample)
WO (1) WO2011133447A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
BR112014030412A2 (pt) 2012-06-14 2017-06-27 Basf Se método para combater ou controlar pragas, método para proteger culturas, compostos, processo para a preparação de compostos, uso de um composto, composição agrícola ou veterinária e semente.
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
KR101823488B1 (ko) 2013-10-14 2018-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
WO2017011788A1 (en) * 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EP3725788A1 (en) 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
CA3148216A1 (en) 2019-07-23 2021-01-28 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
TW202136248A (zh) 2019-11-25 2021-10-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
MX2022010059A (es) 2020-02-18 2022-08-25 Bayer Ag Nuevos compuestos de heteroaril-triazol como pesticidas.
TWI891782B (zh) 2020-05-06 2025-08-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基三唑化合物
MX2024002386A (es) 2021-08-25 2024-03-14 Bayer Ag Nuevos compuestos de pirazinil-triazol como pesticidas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268817B2 (en) * 2006-09-08 2012-09-18 The Scripps Research Institute Substituted oxazole ketone modulators of fatty acid amide hydrolase
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
WO2008150492A1 (en) * 2007-05-31 2008-12-11 The Scripps Research Institute Tricyclic inhibitors of fatty acid amide hydrolase
US20110184026A1 (en) 2008-06-19 2011-07-28 Boger Dale L C4-substituted alpha-keto oxazoles
WO2010017079A1 (en) * 2008-08-04 2010-02-11 Merck & Co., Inc. Oxazole derivatives useful as inhibitors of faah

Also Published As

Publication number Publication date
JP2013525356A (ja) 2013-06-20
WO2011133447A1 (en) 2011-10-27
US20130012526A1 (en) 2013-01-10
CN103153307A (zh) 2013-06-12
EP2593102A4 (en) 2013-12-04
EP2593102A1 (en) 2013-05-22
US9073879B2 (en) 2015-07-07
AU2011242961B2 (en) 2015-09-24
BR112012023971A2 (pt) 2016-11-29
EP2593102B1 (en) 2017-06-07
AU2011242961A1 (en) 2012-09-27
CA2794724A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
JP2013525356A (ja) Faahの調節薬として有用なオキサゾール誘導体
JP5698666B2 (ja) Faahの阻害剤として有用なオキサゾール誘導体
JP2013523814A (ja) Faahの調節薬として有用なオキサゾール誘導体
JP2011523959A (ja) Faahの阻害剤として有用なイミダゾール誘導体
US20110021531A1 (en) Oxazole derivatives useful as inhibitors of faah
JP2013525490A (ja) Faahのモジュレータとして有用なアザインドール誘導体
JP5667093B2 (ja) Faahの調節剤およびfaah造影剤として有用なイミダゾール誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151211

R150 Certificate of patent or registration of utility model

Ref document number: 5856606

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees